Developing Novel Therapies for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 7]: Opportunities From Restorative Neurobiology.

Global Spine J · 2022 · PMC8859698 · PMID 35174725

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

However, by 5-weeks, no significant difference was apparent between the groups. 39 Few human clinical studies have been conducted, though one retrospective study of thoracic myelopathy used intraoperative methylprednisolone found better neurological recovery at 2 weeks, though no significant difference in neurological outcomes between methylprednisolone

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.